Eli Lilly and Company (NYSE:LLY) — Market Cap & Net Worth
Market Cap & Net Worth: Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE:LLY) has a market capitalization of $1.03 Trillion ($1.03 Trillion) as of September 18, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #15 globally and #12 in its home market, demonstrating a 2.51% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eli Lilly and Company's stock price $1152.44 by its total outstanding shares 891741406 (891.74 Million). Also see LLY current and non-current assets for a full breakdown of the balance sheet.
Eli Lilly and Company Market Cap History: 2015 to 2026
Eli Lilly and Company's market capitalization history from 2015 to 2026. Data shows growth from $63.77 Billion to $1.03 Trillion (29.64% CAGR). Also see LLY operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Eli Lilly and Company is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Pharmaceutical
DRG
|
$3.41 Trillion | 30.12% | #1 of 24 |
|
S&P 500 Index
GSPC
|
$62.97 Trillion | 1.27% | #10 of 503 |
|
S&P 100
OEX
|
$45.52 Trillion | 1.81% | #10 of 101 |
Weight: Eli Lilly and Company's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Eli Lilly and Company Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eli Lilly and Company's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Eli Lilly and Company for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
14.70x
Eli Lilly and Company's market cap is 14.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
46.43x
Eli Lilly and Company's market cap is 46.43 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $57.16 Billion | $21.22 Billion | $2.74 Billion | 2.69x | 20.88x |
| 2017 | $67.35 Billion | $19.97 Billion | -$204.10 Million | 3.37x | N/A |
| 2018 | $94.60 Billion | $21.49 Billion | $3.23 Billion | 4.40x | 29.27x |
| 2019 | $109.87 Billion | $22.32 Billion | $8.32 Billion | 4.92x | 13.21x |
| 2020 | $143.97 Billion | $24.54 Billion | $6.19 Billion | 5.87x | 23.24x |
| 2021 | $239.09 Billion | $28.32 Billion | $5.58 Billion | 8.44x | 42.83x |
| 2022 | $320.95 Billion | $28.54 Billion | $6.24 Billion | 11.25x | 51.40x |
| 2023 | $516.44 Billion | $34.12 Billion | $5.24 Billion | 15.13x | 98.55x |
| 2024 | $688.42 Billion | $45.04 Billion | $10.59 Billion | 15.28x | 65.01x |
| 2025 | $958.34 Billion | $65.18 Billion | $20.64 Billion | 14.70x | 46.43x |
Companies Similar to LLY by Market Capitalization
Companies near Eli Lilly and Company in the global market cap rankings as of September 18, 2026. Review Eli Lilly and Company tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Eli Lilly and Company by market ranking:
- Space Exploration Technologies Corp. Class A Common Stock (NASDAQ:SPCX): Ranked #13 globally with a market cap of $1.19 Trillion USD.
- Walmart Inc (SA:WALM34): Ranked #14 globally with a market cap of $1.03 Trillion USD ( R$5.26 Trillion BRL).
- Samsung Electronics Co Ltd (KO:005930): Ranked #16 globally with a market cap of $1.01 Trillion USD ( ₩1483.88 Trillion KRW).
- JPMorgan Chase & Co (NYSE:JPM): Ranked #17 globally with a market cap of $928.53 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #13 | Space Exploration Technologies Corp. Class A Common Stock | NASDAQ:SPCX | $1.19 Trillion | $154.81 |
| #14 | Walmart Inc | SA:WALM34 | $1.03 Trillion | R$41.23 |
| #16 | Samsung Electronics Co Ltd | KO:005930 | $1.01 Trillion | ₩252500.00 |
| #17 | JPMorgan Chase & Co | NYSE:JPM | $928.53 Billion | $349.31 |
Eli Lilly and Company Historical Marketcap From 2015 to 2026
Between 2015 and today, Eli Lilly and Company's market cap moved from $63.77 Billion to $ 1.03 Trillion, with a yearly change of 29.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.03 Trillion | +7.24% |
| 2025 | $958.34 Billion | +39.21% |
| 2024 | $688.42 Billion | +33.30% |
| 2023 | $516.44 Billion | +60.91% |
| 2022 | $320.95 Billion | +34.24% |
| 2021 | $239.09 Billion | +66.07% |
| 2020 | $143.97 Billion | +31.03% |
| 2019 | $109.87 Billion | +16.14% |
| 2018 | $94.60 Billion | +40.45% |
| 2017 | $67.35 Billion | +17.83% |
| 2016 | $57.16 Billion | -10.37% |
| 2015 | $63.77 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Eli Lilly and Company was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.03 Trillion USD |
| MoneyControl | $1.03 Trillion USD |
| MarketWatch | $1.03 Trillion USD |
| marketcap.company | $1.03 Trillion USD |
| Reuters | $1.03 Trillion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 7… Read more